title: Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An18F-FDG PET/CT study.
abstract: The aim of the present study was to investigate brain glucose metabolism in patients with Hodgkin disease (HD) after diagnosis and during chemotherapy treatment. Following the administration of first-line doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy, 74 HD patients underwent18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography brain scans, both baseline (PET0) and interim (PET2) at the Department of Biomedicine and Prevention, University of Rome Tor Vergata (Rome, Italy). Fifty-seven patients were further evaluated 15±6 days after four additional cycles (PET6). Furthermore, a control group (CG) of 40 chemotherapy-naïve subjects was enrolled. Differences in brain18F-FDG uptake between the CG, PET0, PET2 and PET6 scans were analyzed using statistical parametric mapping. Compared with the PET0 and CG scans, the PET2 scan demonstrated a higher metabolic activity in Brodmann area (BA) 39, and a metabolic reduction in BA 11 bilaterally and in left BA 32. All of these changes disappeared at PET6. The results of the present study indicate that ABVD chemotherapy has a limited impact on brain metabolism.
authors.affiliation: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome I-00133, Italy.
authors.forename: Agostino
authors.initials: A
authors.lastname: Chiaravalloti
authors.affiliation: Institute of Cognitive Sciences and Technologies, The National Research Council, Rome I-00185, Italy ; Department of Nuclear Medicine, Karolinska Hospital, Stockholm SE-17176, Sweden.
authors.forename: Marco
authors.initials: M
authors.lastname: Pagani
authors.affiliation: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome I-00133, Italy.
authors.forename: Maria
authors.initials: M
authors.lastname: Cantonetti
authors.affiliation: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome I-00133, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: DI Pietro
authors.affiliation: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome I-00133, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Tavolozza
authors.affiliation: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome I-00133, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Travascio
authors.affiliation: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome I-00133, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: DI Biagio
authors.affiliation: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome I-00133, Italy.
authors.forename: Roberta
authors.initials: R
authors.lastname: Danieli
authors.affiliation: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome I-00133, Italy ; Department of Nuclear Medicine, IRCCS Neuromed, Pozzilli I-86077, Italy.
authors.forename: Orazio
authors.initials: O
authors.lastname: Schillaci
keywords: Hodgkin disease; adriamycin; bleomycin; chemobrain; chemotherapy; positron emission tomography; vinblastine and dacarbazine